Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Serono successfull competitor to Biogen

No earlier versions found for this Subject.

Return to Serono successfull competitor to Biogen

One of the world's top biotechs, Serono focuses on recombinant genetic engineering to develop drugs. With operations in 45 countries ranging from marketing to manufacturing to research and development, the Swiss firm is a leader in reproductive health; flagship drug Gonal-F accounts for 30% of Serono's sales. The firm also focuses on neurological, metabolic, and human growth disorders. Other recombinant products include treatments for multiple sclerosis (Rebif, more than a quarter of sales), growth hormone deficiency, and AIDS-related wasting. With Rebif's approval for MS in the US, Serono hopes to claim market share from leader Biogen.